FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

The U.S. Food and Drug Administration approved Utebzi (tebipenem pivoxil) on June 17, 2026, as a treatment for complicated urinary tract infections (cUTIs) and pyelonephritis in adults. Developed by GSK and Spero Therapeutics, Utebzi is the first oral carbapenem antibiotic approved for these conditions in the United States for patients with limited alternative oral treatment options, according to the agency.

The FDA’s decision targets a specific patient population that previously lacked oral alternatives for severe infections. Pyelonephritis, a type of cUTI that affects the kidneys, often requires potent antibiotics to prevent permanent organ damage or systemic sepsis, according to medical standards reported by Healio News.

How does Utebzi differ from other cUTI treatments?

Utebzi is categorized as a carbapenem, a class of broad-spectrum beta-lactam antibiotics typically reserved for severe, multi-drug resistant infections. Until this approval, carbapenems were administered exclusively via intravenous (IV) infusion in the United States. By providing an oral tablet, Utebzi allows patients to receive this potent class of medication without requiring a hospital stay or a peripherally inserted central catheter.

The drug is specifically indicated for adults who have limited or no other oral treatment options. This restriction ensures the medication is used for resistant strains of bacteria rather than as a first-line therapy, which helps slow the development of further antibiotic resistance.

How does Utebzi compare to the recently approved Zaynich?

Utebzi is the second medication for complicated UTIs approved by the FDA in June 2026. The other approval was for Zaynich (cefepime/zidebactam), developed by Wockhardt. While both drugs target complicated urinary infections, they differ fundamentally in delivery and composition.

• Utebzi: An oral carbapenem antibiotic developed by GSK and Spero Therapeutics.
• Zaynich: An intravenous (IV) formulation of cefepime and zidebactam developed by Wockhardt.

The contrast in delivery methods means that while Zaynich is designed for acute, inpatient stabilization, Utebzi provides a pathway for outpatient management or a faster transition from the hospital to home care.

Why is an oral carbapenem significant for public health?

Antibiotic resistance continues to rise globally, reducing the efficacy of standard oral antibiotics like fluoroquinolones or trimethoprim-sulfamethoxazole. When these first-line treatments fail, physicians have historically been forced to use IV carbapenems, which necessitates hospitalization or outpatient parenteral antimicrobial therapy (OPAT).

Moving a “last-resort” antibiotic class into an oral format reduces the clinical burden on healthcare facilities. It also lowers the risk of catheter-associated bloodstream infections, which can occur when patients require long-term IV access for antibiotic treatment.

“With antibiotic resistance continuing to rise, patients and health care professionals” Healio News

The approval reflects a broader shift in antimicrobial development toward “step-down” therapy. This approach allows a patient to start with a high-potency IV drug to stabilize a severe infection and then switch to an equivalent oral drug, such as Utebzi, to complete the course of treatment at home.

GSK and Spero Therapeutics developed the medication to fill this gap in the care continuum. By providing a pill that maintains the efficacy of a carbapenem, the developers aim to reduce the duration of hospitalizations for adults suffering from complicated kidney and urinary tract infections.